Flubromazolam: Complete Prolonged Intoxication, Pharmacokinetics, Dependence & Safety Monograph

Flubromazolam: Complete Prolonged Intoxication, Pharmacokinetics, Dependence & Safety Monograph

Emergency safety: Profound unresponsiveness, abnormal breathing, blue/gray color, repeated vomiting while deeply sedated, major injury, or suspected opioid co-exposure requires emergency care. If an opioid may also be present, naloxone is appropriate for the opioid component but does not reverse flubromazolam.

Withdrawal safety: Abrupt discontinuation after benzodiazepine-type physical dependence can cause severe withdrawal including seizures and delirium. A long-acting drug can delay withdrawal rather than prevent it.

Quick answer

Flubromazolam is a highly potent designer triazolobenzodiazepine with unusually well-documented prolonged intoxication and a small but useful human pharmacokinetic literature.

It has been sold online since at least 2014 and has no approved medical use in the United States.

Published human evidence documents:

• deep coma;
• acute respiratory failure;
• hypotension;
• prolonged bradycardia;
• rhabdomyolysis;
• extended sedation;
• prolonged detectability in biological samples.

The pharmacokinetic evidence is informative but very small. A widely cited half-life estimate comes from a single controlled self-experiment, not a clinical trial population.

Identity and history

Flubromazolam predates many current designer-benzo products and became a recurring analytical/clinical concern before modern scheduling caught up.

Pharmacology

Like other benzodiazepine-site ligands, flubromazolam enhances inhibitory GABA-A signaling.

Expected effects include:

• sedation;
• anxiolysis;
• muscle relaxation;
• impaired coordination;
• slowed reaction time;
• amnesia;
• disinhibition;
• loss of consciousness at severe exposure.

The compound's reputation for unusually strong/prolonged effects is supported by clinical and PK evidence, but an internet potency ranking still cannot define a safe dose.

Severe human intoxication

A landmark clinical report described a 27-year-old with:

• deep coma;
• bilateral pinpoint unreactive pupils;
• acute respiratory failure;
• hypotension;
• marked creatine-kinase elevation/rhabdomyolysis;
• need for mechanical ventilation and intensive cardiovascular support.

Flubromazolam remained measurable many hours after the reported exposure.

The patient survived after prolonged hospital care.

This case establishes that isolated or predominant flubromazolam exposure can produce life-threatening, prolonged CNS depression.

Prolonged bradycardia

A separate clinical case/review described prolonged bradycardia after flubromazolam purchased online.

The clinical point is broader than heart rate alone:

Designer benzodiazepine toxicity can require sustained respiratory and cardiovascular monitoring well beyond the initial period of perceived intoxication.

Rhabdomyolysis and secondary injury

Severe benzodiazepine intoxication can create harm indirectly through:

• prolonged immobilization;
• hypoxia;
• compression injury;
• agitation/seizure-like activity;
• dehydration.

A 2023 case involving liquid flubromazolam plus clonazolam developed severe rhabdomyolysis and acute kidney injury.

Because more than one designer benzodiazepine was involved, the case does not define a flubromazolam-specific incidence.

Human pharmacokinetics

A 2018 study performed a preliminary PK evaluation using a controlled single-person exposure plus authentic forensic/clinical samples.

The estimated terminal elimination half-life was approximately 10–20 hours.

Urine detection of parent drug and a monohydroxylated metabolite persisted for days under sensitive LC-MS/MS methods.

Why this estimate needs a large warning label

The PK estimate comes from one volunteer.

It does not establish:

• population variability;
• effects of repeated use;
• accumulation after multiple exposures;
• behavior in liver disease;
• interactions with CYP inhibitors/inducers;
• a universal intoxication duration.

A half-life is also not the same thing as “time until sober.”

Metabolism

In-vitro and authentic-sample studies indicate that flubromazolam is primarily metabolized through CYP3A4/5-related pathways.

An important metabolite is:

• alpha-hydroxy-flubromazolam.

Additional conjugated metabolites have been described.

Both parent drug and metabolites can be useful analytical targets depending on specimen and timing.

Interaction implications

CYP3A4/5 involvement makes drug-drug interactions biologically plausible.

The exact magnitude of interaction with individual inhibitors or inducers is not well quantified in controlled human flubromazolam studies.

Testing and detectability

Immunoassay performance can vary by specimen

In the preliminary human PK study, immunochemical assays behaved differently across specimen types/times.

This reinforces a key point: “benzodiazepine screen negative” is not a universal exclusion test for designer benzodiazepines.

Definitive testing

Useful methods include:

• LC-MS/MS;
• LC-QTOF-MS;
• LC-HRMS;
• parent flubromazolam;
• alpha-hydroxy-flubromazolam and other relevant metabolites.

Modern expanded panels are much more reliable than legacy prescription-benzo-only confirmation lists.

Acute toxicity

Severe intoxication can include:

• profound sedation;
• coma;
• respiratory failure;
• hypotension;
• bradycardia;
• aspiration risk;
• rhabdomyolysis/secondary kidney injury;
• prolonged impairment.

Unknown solution concentration and repeated exposure can make accumulation difficult to recognize.

Why long duration changes risk

Longer persistence creates several hazards:

• residual impairment after the person feels improved;
• delayed accumulation with repeated use;
• morning-after driving impairment;
• addition of alcohol or other depressants while substantial drug remains;
• delayed withdrawal after chronic use.

This is why a single half-life estimate should never be used as a “safe redosing” or driving timer.

Opioids, alcohol and other depressants

Highest concern includes:

• fentanyl and other opioids;
• alcohol;
• other benzodiazepines;
• gabapentinoids;
• barbiturates;
• sedative-hypnotics;
• xylazine-containing mixtures.

Benzodiazepines reduce arousal and protective responses; opioids suppress respiratory drive.

The combination can turn profound sedation into a fatal respiratory emergency.

Naloxone

Naloxone does not reverse flubromazolam.

If an unknown product or polysubstance exposure may contain an opioid and the person has slow/abnormal breathing or cannot be awakened, naloxone is appropriate while emergency services are called.

Flumazenil: why published use does not mean home use

Flumazenil has been used in selected medical flubromazolam cases.

That does not make it a routine public antidote.

Flumazenil can precipitate seizures, particularly when:

• benzodiazepine dependence exists;
• the overdose is mixed;
• pro-convulsant co-exposures are possible.

Medical teams weigh those risks against potential benefit.

Tolerance and physical dependence

Repeated benzodiazepine-receptor exposure can produce tolerance and physical dependence.

The exact incidence for flubromazolam has not been established prospectively.

Long duration does not protect against dependence.

Dependence vs benzodiazepine use disorder

Physical dependence is neuroadaptation with withdrawal after exposure decreases.

Benzodiazepine use disorder is a behavioral syndrome involving features such as:

• craving;
• inability to cut down;
• compulsive use;
• continued use despite harm;
• hazardous use;
• interference with responsibilities.

The 2025 multisociety guideline emphasizes that these are not the same diagnosis.

Withdrawal

Possible benzodiazepine withdrawal includes:

• anxiety/panic;
• severe insomnia;
• tremor;
• sweating;
• agitation;
• perceptual disturbance;
• hallucinations;
• confusion;
• seizures;
• delirium.

Long duration can delay onset

A long-acting exposure may create a longer interval before withdrawal becomes obvious.

That delay can falsely reassure someone immediately after stopping.

What is not established

There is no validated flubromazolam-specific:

• withdrawal onset;
• peak;
• total duration;
• seizure incidence;
• diazepam-equivalence conversion;
• self-taper schedule.

Treatment and support

The 2025 multisociety benzodiazepine guideline recommends against abrupt discontinuation when physical dependence is likely and emphasizes individualized clinical management.

That is general benzodiazepine guidance and should not be converted into an unsupervised flubromazolam formula.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Seizures, delirium, severe confusion/hallucinations, major autonomic instability, severe dehydration, or complicated polysubstance withdrawal require urgent medical evaluation.

Forensic interpretation

Prolonged detectability is not prolonged impairment by definition

A drug/metabolite can remain analytically detectable after the most obvious intoxication resolves.

Detection and impairment are related but not identical questions.

Concentration is not dose

Blood concentration varies with:

• timing;
• metabolism;
• tolerance;
• repeated exposure;
• co-drugs;
• specimen type;
• postmortem changes.

No universal fatal concentration

Severe clinical cases demonstrate danger but do not define one blood level above which death is inevitable or below which use is safe.

Counterfeit and product-quality risk

UNODC has documented falsified Xanax containing flubromazolam.

Online powders/solutions add additional uncertainties:

• identity;
• concentration;
• homogeneity;
• contamination;
• labeling accuracy.

A seller's concentration claim is not equivalent to independent analytical confirmation.

Special populations

Controlled flubromazolam data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• respiratory disease/sleep apnea;
• liver/kidney impairment;
• seizure disorders.

Because CYP3A4/5 appears important, liver function and drug interactions are biologically relevant but not well quantified.

Legal and regulatory history

International

WHO reviewed flubromazolam in 2020 and recommended international control.

The UN Commission on Narcotic Drugs placed it in Schedule IV of the 1971 Convention on Psychotropic Substances in 2021.

United States

Flubromazolam was temporarily placed in U.S. Schedule I in 2023.

DEA's final rule permanently placed it in Schedule I effective April 1, 2026.

Myths and misconceptions

“The 10–20 hour half-life is exact for everyone.”
No. It came from a preliminary single-volunteer study.

“Half-life tells you when driving is safe.”
No. Elimination and functional recovery are not the same variable.

“Flumazenil is the Narcan of benzos.”
Misleading and potentially dangerous. Flumazenil has seizure-related contraindications and is a clinician-selected treatment.

“Naloxone reverses flubromazolam.”
No. It reverses opioid effects only.

“A negative benzo screen rules it out.”
Not reliably.

“Long duration means withdrawal is milder.”
Not established. It can instead delay withdrawal onset.

“Dependence means addiction.”
No. They are distinct, though they can coexist.

Evidence ledger

Related evidence

• Designer benzodiazepines overview
• Flubromazepam
• Flualprazolam
• Clonazolam
• Bromazolam
• Diclazepam
• Substance Use, Dependence & Harm Reduction hub

Bottom line

Flubromazolam stands out because its evidence base contains both severe real-world intoxication and a small amount of direct human pharmacokinetic work.

That makes it possible to say more than “strong RC benzo,” but not enough to publish a consumer duration or equivalence chart.

The responsible conclusion is that prolonged CNS depression, accumulation, drug interactions, physical dependence and withdrawal all matter—and that the apparently precise numbers come from much thinner human evidence than they often appear to online.